Results 261 to 270 of about 366,889 (322)

A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results. [PDF]

open access: yesHaemophilia
Hermans C   +17 more
europepmc   +1 more source

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja   +8 more
wiley   +1 more source

Inter-reader agreement of the BI-RADS CEM lexicon. [PDF]

open access: yesEur Radiol
Zarcaro C   +8 more
europepmc   +1 more source

Taste Profile and Relative Bioavailability of Tovorafenib Powder for Oral Suspension and Food Effect of the Tovorafenib Tablet in Healthy Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation,
Yang Zhang   +6 more
wiley   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano   +8 more
wiley   +1 more source

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy